Varian Medical Systems, Inc. and Subsidiaries

CourtUnited States Tax Court
DecidedApril 8, 2026
Docket8435-23
StatusPublished

This text of Varian Medical Systems, Inc. and Subsidiaries (Varian Medical Systems, Inc. and Subsidiaries) is published on Counsel Stack Legal Research, covering United States Tax Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Varian Medical Systems, Inc. and Subsidiaries, (tax 2026).

Opinion

United States Tax Court

166 T.C. No. 8

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES, Petitioner

v.

COMMISSIONER OF INTERNAL REVENUE, Respondent

—————

Docket No. 8435-23. Filed April 8, 2026.

In Varian Med. Sys., Inc. & Subs. v. Commissioner, 163 T.C. 76 (2024), we held that P was entitled to a deduction under I.R.C. § 245A for amounts treated as dividends (DRD) under I.R.C. § 78 for P’s 2018 tax year. We further held that I.R.C. § 245A(d)(1) would disallow P’s foreign tax credits to the extent they were attributable to amounts P properly treated as dividends under I.R.C. § 78 and deducted under I.R.C. § 245A.

Now before us are Cross-Motions for Summary Judgment pertaining to the computation, for the 2018 tax year, of P’s DRD under I.R.C. § 245A and disallowed foreign tax credits under I.R.C. § 245A(d)(1). Specifically, P maintains that (1) as a procedural matter, R is precluded from arguing that I.R.C. § 246 disallows a portion of P’s claimed DRD under I.R.C. § 245A because the argument comes too late; (2) as a substantive matter, I.R.C. § 246 allows P’s claimed DRD in full; and (3) the formula used to compute P’s foreign tax credit disallowance under I.R.C. § 245A(d)(1) must include a pre-I.R.C. § 965(c) amount in the denominator of the fraction. R disagrees with P on each point and contends that P’s arguments regarding I.R.C. § 245A(d)(1) come too late.

Served 04/08/26 2

Held: The Court will not treat R as having forfeited his argument concerning I.R.C. § 246 or P as having forfeited its argument concerning I.R.C. § 245A(d)(1).

Held, further, I.R.C. § 246 disallows a portion of P’s DRD under I.R.C. § 245A.

Held, further, the formula used to compute P’s foreign tax credit disallowance under I.R.C. § 245A(d)(1) must include the post-I.R.C. § 965(c) amount in the denominator of the fraction.

Held, further, R’s Motion will be granted, and P’s Motion will be denied.

Jean A. Pawlow, Eric J. Konopka, and Alexandra B. Clionsky Kelly, for petitioner.

Andrew M. Tiktin, Meenu Kapai, and H. Clifton Bonney, Jr., for respondent.

OPINION

TORO, Judge: In Varian Medical Systems, Inc. & Subs. v. Commissioner, 163 T.C. 76 (2024) (reviewed), the Court addressed two issues of first impression, both related to provisions of the Tax Cuts and Jobs Act (TCJA), Pub. L. No. 115-97, 131 Stat. 2054 (2017).

First, we considered two of the TCJA’s effective date provisions, one that established when a new Code 1 provision (section 245A) would take effect and another that established when changes to a preexisting Code provision (section 78) would take effect. We agreed with petitioner, Varian Medical Systems, Inc. (Varian), that the two effective date provisions created a mismatch, the terms of which had to be respected. As a result, we held that, for certain taxpayers, new section 245A

1 Unless otherwise indicated, statutory references are to the Internal Revenue

Code, Title 26 U.S.C. (I.R.C. or Code), in effect at all relevant times, regulation references are to the Code of Federal Regulations, Title 26 (Treas. Reg.), in effect at all relevant times, and Rule references are to the Tax Court Rules of Practice and Procedure. All monetary amounts have been rounded to the nearest dollar. 3

operated in tandem with the pre-TCJA version of section 78 for a time. Varian was one such taxpayer. Therefore, for its 2018 tax year, we concluded that Varian was entitled to a deduction under section 245A related to gross-up amounts it included in income as a dividend under the prior version of section 78.

Second, we considered whether, in view of our first holding, new section 245A(d)(1) limited the amount of foreign tax credits Varian would be entitled to claim. On this issue, we agreed with the Commissioner and held that Varian’s foreign tax credits would be limited.

After we issued the opinion, Varian and the Commissioner worked to compute Varian’s deduction under section 245A and its disallowed foreign tax credits under section 245A(d)(1). Now before us are Cross-Motions for Summary Judgment addressing disputes that arose during that process. Both parties argue that we should deem certain points raised by the Motions forfeited or abandoned because the other party did not raise them earlier.

For its part, Varian maintains that the Commissioner has forfeited any argument that section 246 disallows a portion of Varian’s claimed deduction under section 245A, and, in any event, section 246 allows Varian’s claimed deduction in full. Varian further contends that, in determining the amount of its foreign tax credit disallowance under section 245A(d)(1), Varian’s net section 965 inclusion must be determined without regard to section 965(c).

The Commissioner disagrees with Varian on each of its three points. Additionally, the Commissioner maintains that Varian has forfeited any arguments regarding the section 245A(d)(1) disallowance.

For the reasons below, we will not treat the parties’ arguments as forfeited and resolve the remaining issues in favor of the Commissioner.

Background

The following facts are derived from the parties’ pleadings and Motion papers. 2 They are stated solely for the purpose of ruling on the

2 Many of these facts were included in our prior opinion. We repeat them here

for the reader’s convenience. 4

Motions before us and not as findings of fact in this case. See Rowen v. Commissioner, 156 T.C. 101, 103 (2021) (reviewed).

Originally founded in 1948, Varian is the parent company of a consolidated group of medical device and software manufacturers. Its principal place of business is in Palo Alto, California.

Varian operates through corporations in many different countries, at least some of which are controlled foreign corporations (CFCs) as that term is defined in section 957(a). Varian and its CFCs are fiscal year taxpayers, meaning their taxable years do not end on December 31. See I.R.C. § 441(a), (d), (e). As relevant for this case, the fiscal year of Varian and its CFCs started on September 30, 2017, and ended on September 28, 2018 (2018 Year).

During the 2018 Year, 22 CFCs owned directly and indirectly by Varian and members of its U.S. consolidated group had Accumulated Post-1986 Deferred Foreign Income, as defined in section 965 and the regulations thereunder. Shares in nine of those CFCs were held directly by a member of Varian’s U.S. consolidated group (first-tier CFCs). Shares in the remaining 13 CFCs were held indirectly (i.e., through one or more foreign corporations) by a member of Varian’s U.S. consolidated group (lower tier CFCs).

Varian filed a consolidated federal income tax return for the 2018 Year. On the return, Varian elected to claim foreign tax credits for foreign taxes that it was deemed to pay under section 960 and was therefore required to “gross up” its taxable income under section 78 by reporting a dividend of approximately $159 million. Varian also claimed a deduction of approximately $60 million under section 245A in connection with the dividend it was treated as receiving under section 78 from its first-tier CFCs.

The Commissioner examined Varian’s tax return and issued Varian a Notice of Deficiency in which, among other things, he disallowed Varian’s claimed deduction under section 245A. The Commissioner also increased Varian’s section 78 dividend by nearly $1.9 million. 3 The Commissioner further determined, in the alternative, that if Varian was entitled to deduct its section 78 dividend under section 245A, then “I.R.C. § 245A(d) would disallow any foreign tax

3 Varian does not dispute this adjustment. 5

credits attributable to that amount. Accordingly, [Varian’s] foreign tax credits [would] be reduced by approximately $6,362,356.”

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Burnet v. Clark
287 U.S. 410 (Supreme Court, 1932)
McFeely v. Commissioner
296 U.S. 102 (Supreme Court, 1935)
Moline Properties, Inc. v. Commissioner
319 U.S. 436 (Supreme Court, 1943)
National Carbide Corp. v. Commissioner
336 U.S. 422 (Supreme Court, 1949)
Perrin v. United States
444 U.S. 37 (Supreme Court, 1979)
California v. Hodari D.
499 U.S. 621 (Supreme Court, 1991)
Connecticut National Bank v. Germain
503 U.S. 249 (Supreme Court, 1992)
Dole Food Co. v. Patrickson
538 U.S. 468 (Supreme Court, 2003)
Lamie v. United States Trustee
540 U.S. 526 (Supreme Court, 2004)
Whitfield v. United States
543 U.S. 209 (Supreme Court, 2005)
United States v. Skoien
614 F.3d 638 (Seventh Circuit, 2010)
Marx v. General Revenue Corp.
133 S. Ct. 1166 (Supreme Court, 2013)
Ford Motor Company v. United States
908 F.3d 805 (Federal Circuit, 2018)
Melida Luna-Garcia De Garcia v. William Barr, U. S
921 F.3d 559 (Fifth Circuit, 2019)
Food Marketing Institute v. Argus Leader Media
588 U.S. 427 (Supreme Court, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Varian Medical Systems, Inc. and Subsidiaries, Counsel Stack Legal Research, https://law.counselstack.com/opinion/varian-medical-systems-inc-and-subsidiaries-tax-2026.